Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kawasaki disease.

Jane W Newburger1, David R Fulton

  • 1Department of Cardiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. jane.newburger@cardio.chboston.org

Current Treatment Options in Cardiovascular Medicine
|May 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Fetal Cerebrovascular Resistance and Neurodevelopment in Congenital Heart Disease: A Physiology-Based Analysis.

Prenatal diagnosis·2026
Same author

Validation of a Briefer Anxiety Screening Tool for Use in Pediatric Cardiology Clinics.

JACC. Advances·2026
Same author

Scoring gene importance by interpreting single-cell foundation models.

Nature biotechnology·2026
Same author

Geospatial Access to Pediatric Cardiac and Cardiac-Surgical Services by Neighborhood-Level Determinants of Health.

Journal of the American Heart Association·2026
Same author

Rare <i>KDR</i> Variants Define a Distinct Genetic Contribution to Congenital Heart Disease.

Circulation. Genomic and precision medicine·2026
Same author

Glucocorticoids in Kawasaki Disease - Refining Indications and the Science.

The New England journal of medicine·2026
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

High-dose intravenous immunoglobulin (IVIG) significantly reduces coronary aneurysms in children with Kawasaki disease. Persistent fever may require a second IVIG dose, with other therapies available for resistant cases.

Area of Science:

  • Pediatric Rheumatology
  • Cardiovascular Medicine
  • Immunology

Background:

  • Kawasaki disease is a critical childhood vasculitis.
  • Coronary artery aneurysms affect up to 25% of children with Kawasaki disease.
  • Early treatment is crucial to prevent cardiac complications.

Purpose of the Study:

  • To outline current management strategies for Kawasaki disease.
  • To detail therapeutic options for preventing and treating coronary artery aneurysms.
  • To discuss long-term management based on aneurysm severity.

Main Methods:

  • Review of current evidence-based guidelines for Kawasaki disease treatment.
  • Description of pharmacological interventions including IVIG, steroids, and antiplatelet/anticoagulant agents.

Related Experiment Videos

  • Discussion of long-term management protocols for coronary artery abnormalities.

    • Main Results:

    • High-dose IVIG in the acute phase reduces coronary aneurysm prevalence fivefold.
    • Persistent fever necessitates a second IVIG infusion.
    • Rescue therapies like steroids and infliximab are used for IVIG-resistant cases.
    • Aspirin is standard, with clopidogrel or anticoagulants added for larger aneurysms.

    Conclusions:

    • Prompt IVIG administration is key to preventing coronary artery aneurysms in Kawasaki disease.
    • Management of coronary aneurysms requires tailored antithrombotic therapy.
    • Long-term care depends on the extent of coronary artery involvement, with limited data on interventions.